Clinical Research on the Effect of Shenkangling Decoction on Frequently Relapsed Nephrotic Syndrome of Children

ZHENG Jian; AI Si; LIN Qing; et al.

doi:10.13288/j.11-2166/r.2009.04.047

您当前的位置：

首页 >

文章列表页 >

Clinical Research on the Effect of Shenkangling Decoction on Frequently Relapsed Nephrotic Syndrome of Children

更新时间：2021-11-17

- Clinical Research on the Effect of Shenkangling Decoction on Frequently Relapsed Nephrotic Syndrome of Children
- Journal of Traditional Chinese Medicine Vol. 50, Issue 4, Pages: 311-313(2009)
- 作者机构：
  
  福建中医学院第一临床医学院儿科
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2009.04.047
  CLC： R272
- Published：2009
- 稿件说明：
移动端阅览
[1]郑健,艾斯,林青,褚克丹,魏金花.肾康灵治疗小儿频复发性肾病与神经内分泌免疫网络关系的临床研究[J].中医杂志,2009,50(04):311-313+316.

ZHENG Jian, AI Si, LIN Qing, et al. Clinical Research on the Effect of Shenkangling Decoction on Frequently Relapsed Nephrotic Syndrome of Children[J]. Journal of Traditional Chinese Medicine2009, 50(4): 311-313.
[1]郑健,艾斯,林青,褚克丹,魏金花.肾康灵治疗小儿频复发性肾病与神经内分泌免疫网络关系的临床研究[J].中医杂志,2009,50(04):311-313+316. DOI： 10.13288/j.11-2166/r.2009.04.047.

ZHENG Jian, AI Si, LIN Qing, et al. Clinical Research on the Effect of Shenkangling Decoction on Frequently Relapsed Nephrotic Syndrome of Children[J]. Journal of Traditional Chinese Medicine2009, 50(4): 311-313. DOI： 10.13288/j.11-2166/r.2009.04.047.

摘要

目的观察益肾活血中药肾康灵治疗小儿频复发性肾病（FRNS）血核因子-κB（NF-κB）、血和尿血栓素B2（TXB2）、6-酮-前列腺素F1α（6-keto-PGF1α）的变化

阐明FRNS患儿的发病机理及肾康灵干预治疗的可能机制。方法收集FRNS患儿60例

采用简单随机法分成治疗组30例、对照组30例。观察FRNS患儿治疗前后血NF-κB、血和尿TXB2、6-keto-PGF1α、皮质醇、24h尿蛋白、血总蛋白（TP）、白蛋白（ALB）、总胆固醇（TC）、甘油三酯（TG）等变化。结果治疗组在降低血NF-κB、血和尿TXB2、血6-keto-PGF1α、血和尿TXB2/6-keto-PGF1α比值和提高血浆皮质醇方面明显优于对照组（P<0.01或P<0.05）。结论肾康灵治疗FRNS患儿的作用机制可能与调节NEI网络功能

改善血液高凝状态有关。

Abstract

Objective To observe the changes of nuclear factor-kappa B （NF-κB） of plasma

thromboxane B2 （TXB2）

and 6-keto-PGF1α of plasma and urine in children with frequently relapsed nephrotic syndrome （FRNS） treated by Shenkangling Decoction （Herbal medicines for kidney diseases） which functions to reinforce kidney and activate blood to study the pathogenesis of FRNS and the functional mechanism of Shenkangling. Methods The 60 children cases with FRNS were randomly divided into treatment group and control group

30 in each. The changes of plasma NF-κB

blood and urine TXB2

6-keto-PGF1α

hydrocortisone

urine protein of 24 hours

serum total protein （TP）

albumin （ALB）

total cholesterol （TC） and triglyceride （TG） before and after treatment were observed. Results In decreasing NF-κB

blood and urine TXB2

6-keto-PGF1α

and TXB2/6-keto-PGF1α and increasing plasma hydrocortisone

the effect of treatment group was significantly better than that of control group （P<0.01 or P<0.05）. Conclusion The mechanism of Shenkangling in treatment of FRNS is possibly related to regulation of NEI and the improvement of hypercoagulative state of blood.

关键词

Keywords

references

查看原文

Views

161

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Study on Najia Method of Midday-Midnight Point Selection for 30 Cases of Acute Ischemic Cerebrovascular Disease

Effect of Reinforcing Kidney and Activating Blood Method on Hydrocortisone,TXB2 and 6-keto-PGF1α in Children FRNS

Challenges and Recommendations for Implementing Key Technologies in Decentralized Clinical Trials of Traditional Chinese Medicine

The Philosophy and Practical Pathway of "Dao （道）-Shen （神）-Formula" in Traditional Chinese Medicine

WANG Qingguo's Experience in Treatment of Headache Based on the Concept of "Achieving Harmony by Unblocking and Balancing"

Related Author

JIANG Hua

WANG Man-xia

GUO Jian

et al.

ZHENG Jian

WEI Jin-hua

WU Qun-li

et al.

Related Institution

Second Hospital of Lanzhou University

兰州大学第二医院中医科甘肃省兰州市城关区萃英门82号

People’s Hospital of Fujian University of Traditional Chinese Medicine

福建中医学院附属人民医院儿科福州市817中路602号

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰